Ferroglobe Q1: Improved Revenue, Slim Loss; Trade Tailwinds Emerge but Profit Elusive

What happened

Ferroglobe reported Q1 2026 revenue of $347.7M, up 5.6% QoQ and 13.2% YoY, driven by stronger ferroalloy pricing and volumes from U.S. trade measures and rising steel production. Net loss narrowed sharply to $7.1M from $81M in Q4 2025, thanks to improved alloy margins and lower energy contract losses. Adjusted EBITDA came in at just $3.3M, underscoring that the earnings inflection remains far from the $25M quarterly threshold needed to confirm a durable recovery. The company highlighted EU support for silicon metal and is actively exploring a restart of Venezuelan operations, while maintaining a healthy cash position of $96.4M and net debt of $54.6M. Despite the top-line improvement, reported earnings remain deeply negative and heavily dependent on trade policy outcomes, with the U.S. final duty determination due around June 22, 2026.

Implication

The Q1 print supports the base case scenario of gradual recovery but fails to trigger the bull case. Adjusted EBITDA of $3.3M is far below the $25M quarterly target that would increase conviction. The company's guidance of $1.5B–$1.7B revenue and $90M–$110M EBITDA for FY2026 implies significant acceleration in coming quarters, which requires both France stability and U.S. duties to materialize. Investors should monitor the June 22, 2026 final duty date and Q2 operational updates for France. Without clear evidence of sustained margin improvement, the stock remains a high-risk policy play. A re-assessment window of 3–6 months is appropriate; the current price near $5.02 offers limited margin of safety.

Thesis delta

Q1 results marginally support the base case (50% probability, $5.75 value) but do not challenge the bear or bull scenarios. Revenue improved, but EBITDA stability remains elusive. The key catalysts—France utilization and U.S. duties—are still pending. The delta is neutral to slightly positive, with the improvement in net loss and cash flow reducing near-term distress risk, but not enough to justify upgrading from WAIT to BUY. The thesis remains dependent on the next two quarters for confirmation of earnings power.